Pfizer Osteoporosis Drug Has More Benefits Than Risks

September 9, 2008

An expert advisory panel has told the FDA that the Pfizer osteoporosis drug Fablyn has more benefits than it does risks......Washington (ChattahBox) – An expert advisory panel has told the FDA that the Pfizer osteoporosis drug Fablyn has more benefits than it does risks.

The Pfizer osteoporosis drug has been rejected by the FDA 3 times already, but is now being recommended for approval.

The drug would be effective in helping postmenopausal woman fight the disease, associated with bone factures.

The advisory panel voted 9-3 in favor of approving the drug, as the benefits outweighed the risks which included blood clots.

The FDA will take this advice and will likely make a deciison in October.

The FDA usually follows the advice of its panels.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.